The Liver Meeting®
57th Annual Meeting of the American
Association for the Study of Liver Diseases


October 27 - 31, 2006
John B. Hynes
Convention Center




Welcome to the HBV Advocate’s AASLD Conference coverage.  In an effort to best serve our readership, we will post all the important and interesting abstracts about HBV from the conference.  While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.  The other abstracts posted to the web site are HBV related abstracts posted to that we have not been able to report on or update.  


To locate specific abstracts for each topic below, click on the links.


Please click here to view our fact sheet on reading and understanding an abstract.


Thank You,

Alan Franciscus





Hepatitis B



Children and Hepatitis B


·        #671. Clearance of HBeAg Is Linked with Emergence of Mutations within Pre-core and Core Regions of Hepatitis B Virus in Pediatric Patients

·        #49. HBeAg Seroconversion Is Associated with HBV-specific T Cell Reactivity of Th1 Lymphocytes and the Emergence of Mutations within HBV Pre-core and Core Regions in Pediatric Patients

·        1316. Positive Impact of Hepatitis B(HB) Video on HB Vaccine Coverage in Homeless Children and Adolescents in Baltimore: Results of a Randomized Controlled Trial.


Diagnostic Tools


·        #978. A Line Probe Assay (LiPA) for Detecting Novel Hepatitis B Drug Resistance Mutations Associated with Entecavir, Tenofovir and Adefovir Dipivoxil Therapy

·        #980. Can ALT and HBV DNA Replace Liver Biopsy for the Evaluation of Hepatitis B Trials?

·        1319. Diagnostic accuracy of MP3, Fibrotest and Hepascore for evaluating liver fibrosis in chronic hepatitis B.


Disease Progression


·        1320. Elevated iron parameters and disease severity in hepatitis B: a more complex relationship than might be assumed.




·        #1006. Chronic Hepatitis B Virus Infection: Disease Characteristics in a Managed Care Population, 1995-2004

·        #1018. Clinical Characteristics of Asian-Americans Infected with Hepatitis B Diagnosed by Community-Based Screenings in New York City

·        1309. Occult HBV infection of transfusion blood products in Korea.  


HBV & Liver Transplantation


·        #779. Anti-HBs-trough-levels and Anti-HBs-half-lives Do Not Differ after Intravenous Versus Intramuscular Hepatitis B Immunoglobulin Administration Given for Long-term Hepatitis B Reinfection Prophylaxis after Liver Transplantation

·        #782. Low Risk of HBV Recurrence Post-liver Transplantation (OLT) in Patients Maintained on Nucleoside(t)e Analogue (NA) Therapy after Withdrawal of Hepatitis B Immune Globulin (HBIG)

·        #786. Presence of Intrahepatic (Total and ccc) HBV DNA Is Not Predictive of HBV Recurrence after Liver Transplant (OLT)


HIV/HBV Coinfection


·        1318. Characteristics, management and evolution of Hepatitis B in HIV infected patients: the prospective multicenter EPIB05 survey. 


Liver Cancer


·        #839. Environmental Factors and Risk of Hepatocellular Carcinoma

·        #840. Does Coffee Drinking Protect Cirrhotic Patients against Hepatocellular Carcinoma?


Liver Imaging


·        #809. Transient Elastography (FibroScan) and FibroTest to Assess Liver Fibrosis in Inactive Hepatitis B Carriers: a Prospective Controlled Study (updated November 1, 2006)


Quality of Life


·        #1015. Development and Validation of a Disease-Targeted Health-Related Quality of Life (HRQOL) Instrument in Chronic Hepatitis B Infection: the HBQOL v1.0

·        1305. High Prevalence of Liver Injury in Patients With Chronic Hepatitis B Virus (HBV) Infection in HBeAg positive subjects with normal ALT. 





Antiviral Treatments for Hepatitis B


·        #966. Mutations at HBV-Polymerase Gene Associated with Entecavir Drug Resistance in Patients Not Undergoing Entecavir Therapy (updated November 1, 2006)

·        #967. Impact of Nucleoside Treatment on Antiviral T-Cell Reactivity in Chronic Hepatitis B: Major Differences Depending on Early Viral Suppression, HBeAg Status and HBV Genotype

·        #968. Emergence of Predominant Adefovir Resistant Mutation during Additive Lamivudine Therapy for Adefovir Resistance in Chronic Hepatitis B Patients with Prior Resistance to Lamivudine (updated November 1, 2006)

·        #969. Long-term Efficacy and Safety of Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B (CHB) Patients

·        # 971. No Evidence for Tenofovir Resistance in Patients with Lamivudine-Resistant HBV Infection During Long-Term Treatment for Up to 5 Years

·        #973. The Effect of Lamivudine on Preventing Hepatocellular Carcinoma in Chronic Hepatitis B: A Retrospective Study of 2,518 Patients

·        #977. HBV cccDNA, Pregenomic RNA and Total HBV DNA Levels in the Liver of Chronic Hepatitis B Patients 4-5 Years from Start of Effective Long-Term Adefovir Dipivoxil Treatment

·        #982. Entecavir Results in Higher HBV DNA Reduction vs Adefovir in Chronically-Infected HBeAg(+) Antiviral-Naive Adults: 24 WK Results (E.A.R.L.Y. Study)

·        #985. Initial Viral Response Is the Most Powerful Predictor of the Emergence of YMDD Mutant Virus in Chronic Hepatitis B Patients Treated with Lamivudine

·        #986. Selection of the A181T/V Substitution in HBV Chronically-Infected Patients Who Developed a Resistance to Lamivudine and/or Adefovir

·        #992. Hepatitis B Surface Antigen Loss in Antiviral-Treated Patients with HBeAg(+) Chronic Hepatits B (CHB) Infection: Observations from Antiviral-Naďve Patients Treated with Entecavir (ETV) or Lamivudine (LVD)

·        #994. Combination of Adefovir Dipivoxil with Lamivudine vs. Adefovir Alone in Lamivudine-Resistant HBeAg-Negative Chronic Hepatitis B Patients

·        #997. Entecavir Achieves Superior Virologic Response Compared to Lamivudine for the Treatment of Chronic Hepatitis B: 2-year Results from a Phase 3 Study in Nucleose-naďve Patients in China (ETV-023)

·        #998. Viral Breakthrough after Emergence of YMDD Mutant Hepatitis B Virus Always Goes to Clinical Breakthrough: Is It Correct?

·        #999. Pre-existing or RapEmergence of A181T Polymerase Mutation in Lamivudine-Resistant Chronic Hepatitis B Patients Treated with Adefovir

·        #1002. Virologic Response Can Be Durable in HBeAg Positive Patients with Chronic Hepatitis B after Lamivudine Monotherapy during Long-term Follow-up?

·        #1004. Hepatitis B Virus Core-related Antigen as an Indicator of Safe Discontinuation of Lamivudine Therapy

·        #1005. A Randomized Trial of Telbivudine (LdT) vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Final Week 52 Results

·        #1007. A Randomized Trial of Telbivudine (LdT) versus Lamivudine in Lamivudine Experienced Patients – Week 24 Primary Analysis

·        #1008. Virologic Response at Treatment Months 12 May Predict Sustained Antiviral Efficacy in Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B

·        #1011. Dynamics of Hepatitis B Virus Resistance to Adefovir Dipivoxil Unraveled by a Thorough Quasispecies Analysis

·        # 1012. Sequential Lamivudine and Adefovir Therapy Maintains Seroconversion Rates In Patients With HBeAg+ Chronic Hepatitis B

·        #1013. Selection of Multidrug-Resistant HBV: Clonal Analysis To Investigate the Complex Evolution of Multiple HBV Mutations

·        #1016. Is Tenofovir Effective in Treatment of Adefovir-Resistant Hepatitis B Virus (HBV) Infections?

·        #1017. Amino AcVariability of the Overlapping Reverse Transcriptase Region of Hepatitis B Surface Antigen in Chronic HBV Carriers with Concomitant Anti-HBs Antibodies in Serum

·        #lB5. Adefovir and Lamivudine Combination Therapy Is Superior to Adefovir Monotherapy for Lamivudine-resistant Patients with HBeAg-Negative Chronic Hepatitis B

·        #D-91  Two-Year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs. Lamivudine

·        #94. Inhibitory Activity of the 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO) Against Wild Type and Drug-Resistant Mutants of HBV

·        1297. Monitoring Interferon And Lamivudine Treatment By Quantitative Measurement Of HBsAG And HDV-RNA Serum Levels In HbeAG-Negative Patients With Chronic Hepatitis Delta.


Cost of Treatment


·        #1003. Modeling for the Most Cost-Effective Treatment Strategy for HBeAg Positive Chronic Hepatitis B




·        #987. Impact of Hepatitis B Genotype on Treatment Response: A Meta-Analysis of Controlled and Uncontrolled Trials

·        #1009. Should Treatment of Hepatitis B Depend on HBV Genotypes? – A Hypothesis Generated from an Explorative Analysis of Published Evidence

·        #989. Low Rates of Genotypic Resistance to Adefovir in Lamivudine-Resistant Patients Treated with Adefovir-Lamivudine Combination Therapy for 3 Years


Pegylated Interferon


·        #970. Significant Reduction of HBsAg in the Sera of HBeAg-Negative Chronic Hepatitis B Patients Treated with Peginterferon Alfa-2a Alone or in Combination with Lamivudine

·        # 972. Suppression of HBV DNA in Patients with HBeAg-negative CHB Treated with Peginterferon Alfa-2a (40KD) ± Lamivudine: 2-Year Follow-up Results

·        #974. Peginterferon Alpha-2B Is Well Tolerated and Leads to High Virological and Histological Response Rates in Chronic Hepatitis B Patients with Advanced Fibrosis

·        #975. Early Peginterferon Alpha-2B Induced HBeAg Loss Results in Increased Rates of HBsAg Loss and Undetectable HBV DNA

·        #996. Induction of CD4+ CD25+ Regulatory T-cells Is Associated with Non-Response to Pegylated Interferon-a Therapy for Chronic Hepatitis B Virus Infection

·        #981. Pegylated Interferon-alfa-2a Plus Adefovir Combination Therapy Is Superior to Pegylated Interferon-alfa-2a Alone or Adefovir Monotherapy in Reducing HBsAg Levels in HDV-Coinfected Patients with Low HBV Viremia

·        #1010. Early Viral Kinetics and Pharmacokinetics in HBeAg-Positive Chronic Hepatitis B Treated with Pegylated Interferon Alpha-2b with or without Lamivudine

·        #1014. Modeling of Pharmacokinetics and Viral Kinetics in HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon Alpha-2b




·        #984. Vaccination with Mature Dendritic Cells Induces Strong HBV Specific Th Cell and CTL Responses in HBV Trimera Mice

·        1304. HBV Vaccine Non-Responsiveness Could be Due to Enhanced Cellular Surface Expression of CD150. 


Viral Resistance & Replication


·        #939. Improvement of the Hepatitis B Virus (HBV) Recombinant Baculovirus-HepG2 System to Study cccDNA Formation and Resistance to Nucleoside Analogs (updated November 1, 2006)

·        #940. Rapid Improvement of Innate Immune Responses and Monocyte Toll-like Receptor-2 (TLR2) Expression during Lamivudine Therapy for Chronic Hepatitis B (CHB)

·        #942. TLR9 Expression and Functional Impairment of Plasmacytoid Dendritic Cells in Patients with Chronic Hepatitis B

·        #945. Influence of Hepatitis B Virus Genotypes as Well as Precore and Core-promoter Mutations on Fulminant Outcome of Acute Infection

·        #947. Viral Quasispecies Evolution in Chronic Hepatitis B: New Light on an Old Story (updated November 1, 2006)

·        #949. Baseline HBV Viral Load and Excess Mortality Associated with Chronic Hepatitis B Infection: The REVEAL-HBV Study

·        #95. Is There a Meaningful Serum HBV DNA Cut-off Level for Therapeutic Decisions in HBeAg-Negative Chronic Hepatitis B (CHBe-)?

·        #96. Immunologic Evidence of Limited Viral Replication in Hepatitis B-Vaccinated Chimpanzees Challenged with a Hepatitis B Polymerase Gene Mutant

·        #963. HBV Surface and Core Protein Expression in the Liver in Chronic Hepatitis B under Long-Term Antiviral Therapy (updated November 1, 2006)